Systemic Idiopathic Juvenile Arthritis-Pipeline Review, H1 2016

Systemic Idiopathic Juvenile Arthritis-Pipeline Review, H1 2016


  • Products Id :- GMDHC8199IDB
  • |
  • Pages: 72
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Systemic Idiopathic Juvenile Arthritis-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Systemic Idiopathic Juvenile Arthritis-Pipeline Review, H1 2016', provides an overview of the Systemic Idiopathic Juvenile Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis

The report reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Idiopathic Juvenile Arthritis therapeutics and enlists all their major and minor projects

The report assesses Systemic Idiopathic Juvenile Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Systemic Idiopathic Juvenile Arthritis Overview 7

Therapeutics Development 8

Pipeline Products for Systemic Idiopathic Juvenile Arthritis-Overview 8

Systemic Idiopathic Juvenile Arthritis-Therapeutics under Development by Companies 9

Systemic Idiopathic Juvenile Arthritis-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Systemic Idiopathic Juvenile Arthritis-Products under Development by Companies 13

Systemic Idiopathic Juvenile Arthritis-Companies Involved in Therapeutics Development 14

Alteogen Inc. 14

Bristol-Myers Squibb Company 15

Epirus Biopharmaceuticals, Inc. 16

Johnson & Johnson 17

Momenta Pharmaceuticals, Inc. 18

Mycenax Biotech Inc. 19

Novartis AG 20

Oncobiologics, Inc. 21

Systemic Idiopathic Juvenile Arthritis-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

abatacept-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

abatacept biosimilar-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

abatacept biosimilar-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

adalimumab biosimilar-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

adalimumab biosimilar-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

adalimumab biosimilar-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

adalimumab biosimilar-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

canakinumab-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

golimumab-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

tocilizumab biosimilar-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

tocilizumab biosimilar-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

tocilizumab biosimilar-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Systemic Idiopathic Juvenile Arthritis-Dormant Projects 59

Systemic Idiopathic Juvenile Arthritis-Discontinued Products 60

Systemic Idiopathic Juvenile Arthritis-Product Development Milestones 61

Featured News & Press Releases 61

Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis 61

Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris 62

May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis 63

Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials 64

Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting 66

Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 67

Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Figures

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Early Stage Products, H1 2016 12

Assessment by Monotherapy Products, H1 2016 22

Number of Products by Targets, H1 2016 23

Number of Products by Stage and Targets, H1 2016 23

Number of Products by Mechanism of Actions, H1 2016 25

Number of Products by Stage and Mechanism of Actions, H1 2016 25

Number of Products by Routes of Administration, H1 2016 27

Number of Products by Stage and Routes of Administration, H1 2016 27

Number of Products by Molecule Types, H1 2016 29

Number of Products by Stage and Molecule Types, H1 2016 29

List of Tables

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Systemic Idiopathic Juvenile Arthritis-Pipeline by Alteogen Inc., H1 2016 14

Systemic Idiopathic Juvenile Arthritis-Pipeline by Bristol-Myers Squibb Company, H1 2016 15

Systemic Idiopathic Juvenile Arthritis-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 16

Systemic Idiopathic Juvenile Arthritis-Pipeline by Johnson & Johnson, H1 2016 17

Systemic Idiopathic Juvenile Arthritis-Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 18

Systemic Idiopathic Juvenile Arthritis-Pipeline by Mycenax Biotech Inc., H1 2016 19

Systemic Idiopathic Juvenile Arthritis-Pipeline by Novartis AG, H1 2016 20

Systemic Idiopathic Juvenile Arthritis-Pipeline by Oncobiologics, Inc., H1 2016 21

Assessment by Monotherapy Products, H1 2016 22

Number of Products by Stage and Target, H1 2016 24

Number of Products by Stage and Mechanism of Action, H1 2016 26

Number of Products by Stage and Route of Administration, H1 2016 28

Number of Products by Stage and Molecule Type, H1 2016 30

Systemic Idiopathic Juvenile Arthritis-Dormant Projects, H1 2016 59

Systemic Idiopathic Juvenile Arthritis-Discontinued Products, H1 2016 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alteogen Inc.

Bristol-Myers Squibb Company

Epirus Biopharmaceuticals, Inc.

Johnson & Johnson

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Novartis AG

Oncobiologics, Inc.

Systemic Idiopathic Juvenile Arthritis Therapeutic Products under Development, Key Players in Systemic Idiopathic Juvenile Arthritis Therapeutics, Systemic Idiopathic Juvenile Arthritis Pipeline Overview, Systemic Idiopathic Juvenile Arthritis Pipeline, Systemic Idiopathic Juvenile Arthritis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com